A Study Of The Safety And Effectiveness Of A New Treatment For Allergic Conjunctivitis

This study has been withdrawn prior to enrollment.
(Study withdrawn without starting or enrolling subjects due to a business decision to not proceed with the project.)
Sponsor:
Information provided by (Responsible Party):
Bausch & Lomb Incorporated
ClinicalTrials.gov Identifier:
NCT00375596
First received: September 12, 2006
Last updated: February 19, 2015
Last verified: February 2015

September 12, 2006
February 19, 2015
Not Provided
Not Provided
Safety and efficacy of a new allergy medication [ Time Frame: 0 ] [ Designated as safety issue: No ]
STUDY WITHDRAWN PRIOR TO OUTCOME DETERMINATION
Not Provided
Complete list of historical versions of study NCT00375596 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
A Study Of The Safety And Effectiveness Of A New Treatment For Allergic Conjunctivitis
Study Withdrawn Prior to Determining Official Title
This study will evaluate the safety and efficacy of a new allergy medication
Study withdrawn prior to determining study details
Interventional
Phase 2
Intervention Model: Parallel Assignment
Allergic Conjunctivitis
Drug: Ketotifen/vasoconstrictor
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Withdrawn
0
Not Provided
Not Provided

Inclusion Criteria:

  • Be at least 6 years of age, of any race, or either gender.
  • Have a positive allergic history of ocular allergies and a positive skin test reaction to cat hair/dander, ragweed, tree and/or grass pollen within the past 24 months.
  • Have a calculated best-corrected visual acuity of 0.6 logMar or better in each eye as measured using an ETDRS chart.
  • Positive bilateral CAC reaction at Visit 1 & 2.

Exclusion Criteria:

  • Have any known contraindications, allergies, or sensitivities to the use of any of the study medications, or their components.
  • Any ocular condition that, in the opinion of the investigator, could affect the subject's safety or trial parameters
  • Manifest signs or symptoms of clinically active allergic conjunctivitis in either eye at the baseline slit-lamp exam of any visit
Both
6 Years and older   (Child, Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
United States
 
NCT00375596
C-02-06-001
No
Not Provided
Not Provided
Bausch & Lomb Incorporated
Bausch & Lomb Incorporated
Not Provided
Not Provided
Bausch & Lomb Incorporated
February 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP